红色生物技术市场：按产品类型、按应用、按最终用户、按地区

2025年红色生物技术市场价值估计为9,1026亿美元，预计到2032年将达到18,543.8亿美元，2025年至2032年的复合年增长率为10.7%。

红色生物技术，又称为医疗生物技术，是生物技术的子部门，专注于医疗保健应用，利用生物技术开发新药物、治疗方法和医疗技术来治疗或预防疾病。

市场动态：

红色生物技术市场受多种因素驱动，包括人口老化、慢性病发病率上升以及疫情导致的全球医疗保健需求成长。基因组学、个人化医疗和基因治疗的进步也是主要驱动因素。此外，政府投资、监管支援以及私营部门日益增长的兴趣也促进了红色生物技术的发展，因为它致力于开发创新的治疗方法和治疗方法。

然而，生技药品药物开发的高成本预计会抑制市场成长。

本研究的主要特点

• 本研究报告对全球红色生物技术市场进行了详细分析，并提供了预测期（2025-2032）的市场规模和年复合成长率（CAGR%），假设2024年为基准年。
• 它还揭示了各个领域的潜在商机，并解释了该市场的有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
• 全球红色生物技术市场的主要企业根据公司亮点、产品系列、关键亮点、财务绩效和策略等参数进行分析。
• 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球红色生物技术市场报告迎合了该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进入者和金融分析师。
• 透过用于分析全球红色生物技术市场的各种策略矩阵，相关人员将更容易做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章市场动态、法规与趋势分析

• 市场动态
  • 慢性病盛行率不断上升
  • 生技药品的定价压力
  • 生物技术在农业的应用
• 影响分析
• 主要亮点
• 监管情景
• 产品发布/核准
• PEST分析
• 波特分析
• 併购场景

4. 全球红色生物技术市场-冠状病毒（COVID-19）大流行的影响

• COVID-19流行病学
• 供需侧分析
• 经济影响

5. 全球红色生物技术市场（依产品类型），2020-2032

• 生物製药
• 生物相似药
• 基因治疗
• 组织工程
• 细胞疗法

6. 全球红色生物技术市场（按应用）2020-2032

• 药物研发
• 动物生物技术
• 环境生物技术
• 医学生物技术
• 工业生物技术
• 农业生物技术
• 其他的

7. 全球红色生物技术市场（按最终用户划分），2020-2032 年

• 製药和生物製药公司
• 研究机构
• 生技产业
• 医院和诊断中心
• 学术机构

8. 2020-2032 年全球红色生物技术市场（按地区）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 南非
  • 北非
  • 中部非洲

第九章 竞争态势

• Amgen Inc.
• Gilead Sciences, Inc.
• Biogen
• Pfizer Inc.
• Novartis AG
• Hoffmann-La Roche
• Johnson & Johnson Services, Inc.
• Sanofi
• Merck & Co. Inc.
• AbbVie Inc.
• GSK plc.
• AstraZeneca
• Eli Lilly and Company
• Novo Nordisk A/S
• Bayer AG
• Bristol-Myers Squibb Company
• Teva Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH
• Astellas Pharma Inc.

第 10 章 章节

• 调查方法
• 关于出版商

Red Biotechnology Market is estimated to be valued at USD 910.26 Bn in 2025 and is expected to reach USD 1,854.38 Bn by 2032, growing at a compound annual growth rate (CAGR) of 10.7% from 2025 to 2032.

Red biotechnology, also known as medical biotechnology, is a subsector of biotechnology that focuses on medical and healthcare applications. It involves the use of biotechnology techniques to develop new drugs, therapies, and medical technologies for the treatment and prevention of diseases.

Market Dynamics:

Red biotechnology market is driven by several factors. These include the increasing global healthcare needs due to aging populations, rising chronic diseases, and pandemics. Advances in genomics, personalized medicine, and gene therapies are also key drivers. Additionally, government investments, regulatory support, and growing private sector interest contribute to the growth of red biotechnology, which aims to develop innovative medical treatments and therapies.

However, high costs associated with biologics drug development is expected to restrain the market growth.

Key features of the study:

• This report provides in-depth analysis of the global red biotechnology market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global red biotechnology market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen, Gilead Sciences, Biogen, Pfizer, Novartis, Roche, Johnson & Johnson, Sanofi, Merck & Co., AbbVie, GlaxoSmithKline, AstraZeneca, Eli Lilly, Novo Nordisk, Bayer, Bristol-Myers Squibb, Teva Pharmaceutical, Takeda Pharmaceutical, Boehringer Ingelheim, and Astellas Pharma
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global red biotechnology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global red biotechnology market

Red Biotechnology Market Detailed Segmentation:

• By Product Type
  • Biopharmaceuticals
  • Biosimilars
  • Gene Therapy
  • Tissue Engineering
  • Cell Therapy
• By Application
  • Drug Discovery & Development
  • Animal Biotechnology
  • Environmental Biotechnology
  • Medical Biotechnology
  • Industrial Biotechnology
  • Agricultural Biotechnology
  • Others
• By End User
  • Pharmaceutical & Biopharmaceutical Companies
  • Research Institutes
  • Biotechnology Industry
  • Hospitals & Diagnostic Centers
  • Academic Institutions
• Company Profiles
  • Amgen
  • Gilead Sciences
  • Biogen
  • Pfizer
  • Novartis
  • Roche
  • Johnson & Johnson
  • Sanofi
  • Merck & Co.
  • AbbVie
  • GlaxoSmithKline
  • AstraZeneca
  • Eli Lilly
  • Novo Nordisk
  • Bayer
  • Bristol-Myers Squibb
  • Teva Pharmaceutical
  • Takeda Pharmaceutical
  • Boehringer Ingelheim
  • Astellas Pharma

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Product Type
  • Market Snippet, By Application
  • Market Snippet , By End User
  • Market Snippet , By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing prevalence of chronic diseases
  • Pricing pressures on biologics
  • Biotech applications in agriculture
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Global Red Biotechnology Market - Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Red Biotechnology Market, By Product Type, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Biopharmaceuticals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Biosimilars
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Gene Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Tissue Engineering
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Cell Therapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Global Red Biotechnology Market, By Application, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Drug Discovery & Development
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Animal Biotechnology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Environmental Biotechnology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Medical Biotechnology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Industrial Biotechnology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Agricultural Biotechnology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

7. Global Red Biotechnology Market, By End User, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pharmaceutical & Biopharmaceutical Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Research Institutes
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Biotechnology Industry
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Hospitals & Diagnostic Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Academic Institutions
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

8. Global Red Biotechnology Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Amgen Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Gilead Sciences, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Biogen
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hoffmann-La Roche
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Johnson & Johnson Services, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sanofi
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Merck & Co. Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• AbbVie Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• AstraZeneca
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Novo Nordisk A/S
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Bayer AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Boehringer Ingelheim International GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Astellas Pharma Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us